AbCellera Biologics Statistics
Total Valuation
ABCL has a market cap or net worth of $851.58 million. The enterprise value is $274.72 million.
Important Dates
The last earnings date was Monday, November 4, 2024, after market close.
| Earnings Date | Nov 4, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
ABCL has 294.67 million shares outstanding. The number of shares has increased by 1.70% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 294.67M |
| Shares Change (YoY) | +1.70% |
| Shares Change (QoQ) | +0.22% |
| Owned by Insiders (%) | 26.67% |
| Owned by Institutions (%) | 30.58% |
| Float | 188.55M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 25.69 |
| Forward PS | 21.26 |
| PB Ratio | 0.79 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 8.33 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.34, with a Debt / Equity ratio of 0.06.
| Current Ratio | 9.34 |
| Quick Ratio | 8.48 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -15.55% and return on invested capital (ROIC) is -15.99%.
| Return on Equity (ROE) | -15.55% |
| Return on Assets (ROA) | -13.26% |
| Return on Capital (ROIC) | -15.99% |
| Revenue Per Employee | $56,249 |
| Profits Per Employee | -$299,995 |
| Employee Count | 586 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -26.37M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -38.51% in the last 52 weeks. The beta is 0.35, so ABCL's price volatility has been lower than the market average.
| Beta (5Y) | 0.35 |
| 52-Week Price Change | -38.51% |
| 50-Day Moving Average | 2.63 |
| 200-Day Moving Average | 3.61 |
| Relative Strength Index (RSI) | 59.59 |
| Average Volume (20 Days) | 1,867,474 |
Short Selling Information
The latest short interest is 17.35 million, so 5.89% of the outstanding shares have been sold short.
| Short Interest | 17.35M |
| Short Previous Month | 17.06M |
| Short % of Shares Out | 5.89% |
| Short % of Float | 9.20% |
| Short Ratio (days to cover) | 10.12 |
Income Statement
In the last 12 months, ABCL had revenue of $32.96 million and -$175.80 million in losses. Loss per share was -$0.61.
| Revenue | 32.96M |
| Gross Profit | -142.70M |
| Operating Income | -308.06M |
| Pretax Income | -178.81M |
| Net Income | -175.80M |
| EBITDA | -222.24M |
| EBIT | -308.06M |
| Loss Per Share | -$0.61 |
Full Income StatementBalance Sheet
The company has $643.14 million in cash and $66.27 million in debt, giving a net cash position of $576.87 million or $1.96 per share.
| Cash & Cash Equivalents | 643.14M |
| Total Debt | 66.27M |
| Net Cash | 576.87M |
| Net Cash Per Share | $1.96 |
| Equity (Book Value) | 1.08B |
| Book Value Per Share | 3.65 |
| Working Capital | 663.32M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$120.17 million and capital expenditures -$77.20 million, giving a free cash flow of -$197.36 million.
| Operating Cash Flow | -120.17M |
| Capital Expenditures | -77.20M |
| Free Cash Flow | -197.36M |
| FCF Per Share | -$0.67 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -934.60% |
| Pretax Margin | -613.34% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -515.51% |